# IGC Pharma, Inc.: filings

IGC · NYSE · CIK 1326205 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/igc.md) · [Financials](/companies/igc/financials.md) · [Filings](/companies/igc/filings.md) · [Insiders](/companies/igc/insiders.md)

## Reports and events: 270 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (8-K 158, 4 96, 10-Q 53, CORRESP 52, UPLOAD 36, 424B5 20, 10-K 17, 5 17, DEF 14A 17, SC 13G/A 17, EFFECT 16, NT 10-Q 15, S-3 13, S-3/A 12, NT 10-K 11, S-1/A 10, 144 7, POS AM 7, S-8 7, 3 6, PRE 14A 6, 5/A 5, SC 13G 5, 10-K/A 4, DEFA14A 4, 424B3 3, 4/A 3, 8-K/A 3, SC 13D 3, SC TO-I/A 3, S-1 2, SC 13D/A 2, 10-KT 1, 10-Q/A 1, 25 1, 25-NSE 1, 3/A 1, 424B4 1, ARS 1, AW 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-22 | 00:32 ET | [DEF 14A](/filings/0001185185-26-004896.md) | Proxy statement, period 2026-12-02 | 0001185185-26-004896 |
| 2026-08-14 | 20:01 ET | [10-Q](/filings/0001185185-26-003544.md) | Quarterly report, period 2026-06-30 | 0001185185-26-003544 |
| 2026-07-14 | 22:11 ET | [8-K](/filings/0001185185-26-002922.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001185185-26-002922 |
| 2026-07-06 | 20:02 ET | [8-K](/filings/0001185185-26-002808.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001185185-26-002808 |
| 2026-06-08 | 20:03 ET | [8-K](/filings/0001185185-26-002410.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001185185-26-002410 |
| 2026-05-15 | 20:02 ET | [10-Q](/filings/0001185185-26-001885.md) | Quarterly report, period 2026-03-31 | 0001185185-26-001885 |
| 2026-04-20 | 20:01 ET | [8-K](/filings/0001185185-26-001437.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001185185-26-001437 |
| 2026-03-30 | 21:43 ET | [8-K](/filings/0001185185-26-001146.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-26-001146 |
| 2026-03-12 | 22:19 ET | [8-K](/filings/0001185185-26-000846.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001185185-26-000846 |
| 2026-01-06 | 23:11 ET | [8-K](/filings/0001185185-26-000032.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001185185-26-000032 |
| 2026-01-02 | 21:02 ET | [8-K](/filings/0001185185-26-000010.md) | 5.03 Amendment to articles or bylaws | 0001185185-26-000010 |
| 2025-12-15 | 21:02 ET | [8-K](/filings/0001185185-25-002055.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001185185-25-002055 |
| 2025-11-14 | 21:11 ET | [10-Q](/filings/0001185185-25-001752.md) | Quarterly report, period 2025-09-30 | 0001185185-25-001752 |
| 2025-11-14 | 15:03 ET | [8-K](/filings/0001185185-25-001713.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001185185-25-001713 |
| 2025-10-14 | 23:49 ET | [8-K](/filings/0001185185-25-001428.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-25-001428 |
| 2025-10-01 | 20:40 ET | [8-K](/filings/0001185185-25-001326.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001185185-25-001326 |
| 2025-08-18 | 19:02 ET | [DEF 14A](/filings/0001185185-25-001021.md) | Proxy statement, period 2025-10-10 | 0001185185-25-001021 |
| 2025-08-14 | 20:04 ET | [10-Q](/filings/0001185185-25-000997.md) | Quarterly report, period 2025-06-30 | 0001185185-25-000997 |
| 2025-06-27 | 20:14 ET | [10-K](/filings/0001185185-25-000706.md) | Annual report, period 2025-03-31 | 0001185185-25-000706 |
| 2025-06-17 | 12:36 ET | [8-K](/filings/0001185185-25-000657.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-25-000657 |
| 2025-02-14 | 21:00 ET | [10-Q](/filings/0001185185-25-000137.md) | Quarterly report, period 2024-12-31 | 0001185185-25-000137 |
| 2024-11-12 | 21:04 ET | [10-Q](/filings/0001185185-24-001096.md) | Quarterly report, period 2024-09-30 | 0001185185-24-001096 |
| 2024-09-27 | 20:05 ET | [8-K](/filings/0001185185-24-000923.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001185185-24-000923 |
| 2024-08-27 | 22:38 ET | [8-K](/filings/0001185185-24-000851.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-24-000851 |
| 2024-08-14 | 20:23 ET | [SC 13D/A](/filings/0001185185-24-000811.md) | Ownership report, active investor, amended | 0001185185-24-000811 |
| 2024-08-07 | 20:03 ET | [10-Q](/filings/0001185185-24-000766.md) | Quarterly report, period 2024-06-30 | 0001185185-24-000766 |
| 2024-08-02 | 18:38 ET | [8-K](/filings/0001185185-24-000755.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001185185-24-000755 |
| 2024-07-08 | 20:07 ET | [DEF 14A](/filings/0001185185-24-000674.md) | Proxy statement, period 2024-08-23 | 0001185185-24-000674 |
| 2024-06-24 | 17:32 ET | [10-K](/filings/0001185185-24-000650.md) | Annual report, period 2024-03-31 | 0001185185-24-000650 |
| 2024-05-21 | 01:20 ET | [SC 13D](/filings/0001185185-24-000580.md) | Ownership report, active investor | 0001185185-24-000580 |
| 2024-04-05 | 15:33 ET | [8-K](/filings/0001185185-24-000360.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-24-000360 |
| 2024-03-28 | 22:42 ET | [8-K](/filings/0001185185-24-000324.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-24-000324 |
| 2024-03-22 | 23:34 ET | [8-K](/filings/0001185185-24-000301.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001185185-24-000301 |
| 2024-03-13 | 13:00 ET | [8-K](/filings/0001185185-24-000233.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001185185-24-000233 |
| 2024-02-14 | 21:03 ET | [10-Q](/filings/0001185185-24-000160.md) | Quarterly report, period 2023-12-31 | 0001185185-24-000160 |
| 2023-11-09 | 22:15 ET | [10-Q](/filings/0001185185-23-001163.md) | Quarterly report, period 2023-09-30 | 0001185185-23-001163 |
| 2023-10-27 | 21:21 ET | [8-K](/filings/0001185185-23-001111.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001185185-23-001111 |
| 2023-08-21 | 16:44 ET | [8-K](/filings/0001185185-23-000887.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-23-000887 |
| 2023-08-10 | 20:10 ET | [10-Q](/filings/0001185185-23-000796.md) | Quarterly report, period 2023-06-30 | 0001185185-23-000796 |
| 2023-07-26 | 21:26 ET | [DEF 14A](/filings/0001185185-23-000759.md) | Proxy statement, period 2023-08-18 | 0001185185-23-000759 |
| 2023-07-07 | 20:15 ET | [10-K](/filings/0001185185-23-000693.md) | Annual report, period 2023-03-31 | 0001185185-23-000693 |
| 2023-07-07 | 15:41 ET | [8-K](/filings/0001185185-23-000691.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001185185-23-000691 |
| 2023-07-07 | 21:52 ET | [8-K](/filings/0001185185-23-000688.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001185185-23-000688 |
| 2023-05-08 | 22:19 ET | [8-K](/filings/0001185185-23-000448.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001185185-23-000448 |
| 2023-03-21 | 20:50 ET | [8-K](/filings/0001185185-23-000238.md) | 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001185185-23-000238 |
| 2023-02-14 | 21:02 ET | [10-Q](/filings/0001185185-23-000133.md) | Quarterly report, period 2022-12-31 | 0001185185-23-000133 |
| 2022-12-29 | 14:19 ET | [8-K](/filings/0001185185-22-001458.md) | 5.02 Departure or appointment of officers or directors | 0001185185-22-001458 |
| 2022-12-20 | 13:23 ET | [8-K](/filings/0001185185-22-001432.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001185185-22-001432 |
| 2022-11-01 | 20:07 ET | [10-Q](/filings/0001185185-22-001243.md) | Quarterly report, period 2022-09-30 | 0001185185-22-001243 |
| 2022-09-09 | 20:55 ET | [8-K](/filings/0001185185-22-001082.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-22-001082 |

Page 1 of 6. [Older](/companies/igc/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:11 ET. No prices; not investment advice.